高级搜索
苏文中, 李守淼, 周光辉, 王虎, 胡广杰, 黄艳玲, 李黎, 马华兵. 食管胃结合部腺癌中HSP105b的表达与腹腔热灌注化疗疗效的关系[J]. 肿瘤防治研究, 2021, 48(4): 365-369. DOI: 10.3971/j.issn.1000-8578.2021.20.0824
引用本文: 苏文中, 李守淼, 周光辉, 王虎, 胡广杰, 黄艳玲, 李黎, 马华兵. 食管胃结合部腺癌中HSP105b的表达与腹腔热灌注化疗疗效的关系[J]. 肿瘤防治研究, 2021, 48(4): 365-369. DOI: 10.3971/j.issn.1000-8578.2021.20.0824
SU Wenzhong, LI Shoumiao, ZHOU Guanghui, WANG Hu, HU Guangjie, HUANG Yanling, LI Li, MA Huabing. Expression of Heat Shock Protein 105b in Adenocarcinoma of Esophagogastric Junction and Its Relation with Effect of Hyperthermic Intraperitoneal Chemotherapy[J]. Cancer Research on Prevention and Treatment, 2021, 48(4): 365-369. DOI: 10.3971/j.issn.1000-8578.2021.20.0824
Citation: SU Wenzhong, LI Shoumiao, ZHOU Guanghui, WANG Hu, HU Guangjie, HUANG Yanling, LI Li, MA Huabing. Expression of Heat Shock Protein 105b in Adenocarcinoma of Esophagogastric Junction and Its Relation with Effect of Hyperthermic Intraperitoneal Chemotherapy[J]. Cancer Research on Prevention and Treatment, 2021, 48(4): 365-369. DOI: 10.3971/j.issn.1000-8578.2021.20.0824

食管胃结合部腺癌中HSP105b的表达与腹腔热灌注化疗疗效的关系

Expression of Heat Shock Protein 105b in Adenocarcinoma of Esophagogastric Junction and Its Relation with Effect of Hyperthermic Intraperitoneal Chemotherapy

  • 摘要:
    目的 探讨热休克蛋白(HSP)105b在进展期食管胃结合部腺癌(AEG)组织中的表达情况及与临床病理特征和腹腔热灌注化疗疗效的关系。
    方法 将安阳市肿瘤医院收治的行开腹根治性R0切除+D2淋巴结清除术的166例进展期AEG患者随机分为治疗组(预防性术后紫杉醇腹腔热灌注化疗)和对照组(常规处理)。免疫组织化学法检测术后癌组织中HSP105b的表达水平,分析其表达水平与临床病理特征及腹腔热灌注化疗疗效的关系。
    结果 HSP105b的表达水平仅与肿瘤静脉浸润相关(t=4.002, P=0.045)。HSP105b高表达者3年无瘤生存率明显低于低表达者(56.5% vs. 64.8%, χ2=35.508, P < 0.001),而且治疗组中HSP105b高表达患者3年无瘤生存率明显低于低表达患者(60.7% vs. 71.5%, χ2=77.459, P < 0.001)。
    结论 HSP105b是食管胃交界部腺癌的预后不良指标,其表达水平可以预测腹腔热灌注化疗的疗效。

     

    Abstract:
    Objective To explore the expression of heat shock protein (HSP) 105b in advanced adenocarcinoma of esophagogastric junction (AEG) patients and its relation with clinicopathological characteristics and effect of hyperthermic intraperitoneal chemotherapy (HIPEC).
    Methods We randomly divided 166 cases of advanced AEG who underwent open radical gastrectomy and lymphadenectomy D2 compartment into treatment group (prophylactic HIPEC of paclitaxel after operation) and control group (conventional treatment). Immunohistochemistry was used to detect HSP105b expression in postoperative tumor tissues, and to analyze its relation with clinicopathological characteristics and effect of HIPEC.
    Results The expression of HSP105b was only associated with tumor vein infiltration (t=4.002, P=0.045). The 3-year disease-free survival rate of the patients with high HSP105b expression was significantly lower than those with low HSP105b expression (56.5% vs. 64.8%, χ2=35.508, P < 0.001), and the disease-free survival rate of the patients with high HSP105b expression in treatment group was significantly lower than that with low HSP105b expression (60.7% vs. 71.5%, χ2=77.459, P < 0.001).
    Conclusion HSP105b can be used as a prognostic factor and its expression can predict the efficacy of HIPEC in the patients with advanced AEG.

     

/

返回文章
返回